NCT02628704 2023-01-26
SCORE
Karyopharm Therapeutics Inc
Phase 2 Withdrawn
Clinical Trials
6 trialsNCT04288765 2021-07-09
Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma
Grupo Cooperativo de HemopatÃas Malignas
Phase 3 Withdrawn
NCT02802163 2017-04-25
Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Withdrawn
NCT01812720 2016-12-19
CARAMEL 2
Mayo Clinic
Phase 2 Withdrawn
NCT02756663 2016-11-08
PANORAMA-5
Novartis
Phase 2 Withdrawn
NCT02114502 2014-07-11
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
M.D. Anderson Cancer Center
Phase 2 Withdrawn